Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: Implications in Parkinson's disease

Brain Research

Volumn 1139, Issue 1, 2007, Pages 195-200

  Jana, Sirsendu ^a   Maiti, Arpan Kumar ^a   Bagh, Maria Bindu ^a   Banerjee, Kalpita ^a   Das, Amitabha ^a   Roy, Arun ^b   Chakrabarti, Sasanka ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF CALCUTTA   (India)

Author keywords

Clorgyline; Dopamine; Mitochondria; Parkinson's disease; Quinone

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CLORGYLINE; CYANIDE; DOPAMINE; PROTEIN DERIVATIVE; QUINOPROTEIN; THIOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOOXIDATION; BRAIN; CATALYSIS; CATALYST; ENZYME ACTIVITY; ENZYME INHIBITION; MITOCHONDRION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BENZOQUINONES; BRAIN; DOPAMINE; ELECTRON TRANSPORT; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; MITOCHONDRIA; OXIDATION-REDUCTION; PARKINSON DISEASE; RATS; RATS, INBRED STRAINS;

RATTUS;

EID: 33847283651     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.09.100     Document Type: Article

References (24)

1. Beal M.F. Mitochondrial oxidative damage and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 120-131
2. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 (1999) 1127-1137
3. Clark J.B., Bates T.E., Boakye P., Kuimov A., and Land J.M. Investigation of mitochondrial defects in brain and skeletal muscle. In: Turner A.J., and Bachelard H.S. (Eds). Neurochemistry: A Practical Approach (1997), Oxford Univ. Press Inc, New York 151-174
4. Cohen G., Farooqui R., and Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4890-4894
5. Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Daniel S.E., Lees A.J., Schapira A.H.V., Jenner P., and Marsden C.D. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35 (1994) 38-44
6. 2 and hydroxyl radicals but not glutathione-protein-mixed disulfides. J. Neurochem. 82 (2002) 66-74
7. Gluck M.R., and Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases. J. Neurochem. 91 (2004) 788-795
8. Greenamyre J.T., MacKenzie G., Peng T., and Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66 (1999) 85-97
9. Greggio E., Bergantino E., Carter D., Ahmad R., Costin G.E., Hearing V.J., Clarimon J., Singleton A., Erola J., Hellstrom O., Tienari P.J., Miller D.W., Beilina A., Bubacco L., and Cookson M.R. Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. J. Neurochem. 93 (2005) 246-256
10. Habeeb A.F.S.A. Reaction of protein sulfhydryl groups with Ellman's reagent. Methods Enzymol. 25 (1972) 457-464
11. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1956-1961
12. Hatefi Y. Preparation and properties of NADH:ubiquinone oxidoreductase (complex I) E.C. 1,6,5,3. Methods Enzymol. 53 (1978) 11-15
13. Jenner P., and Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Neurology 66 (2006) S24-S36
14. Khan F.H., Saha M., and Chakrabarti S. Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain Res. 895 (2001) 245-249
15. Khan F.H., Sen T., Maiti A.K., Jana S., Chatterjee U., and Chakrabarti S. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim. Biophys. Acta 1741 (2005) 65-74
16. Li H., and Dryhurst G. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69 (1997) 1530-1541
17. Li H., Shen X.M., and Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J. Neurochem. 71 (1998) 2049-2062
18. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with Folin-Phenol reagent. J. Biol. Chem. 193 (1951) 265-275
19. Matsunaga J., Sinha D., Pannell L., Santis C., Solano F., Wistow G.J., and Hearing V.J. Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J. Biol. Chem. 274 (1999) 3268-3271
20. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
21. Przedborski S., Jacobson-Lewis V., and Fahn S. Antiparkinsonian therapies and brain mitochondrial complex-I activity. Mov. Disord. 10 (1995) 312-317
22. Riederer P., Sofie E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., and Youdim M.B.H. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J. Neurochem. 52 (1989) 515-520
23. Spencer J.P.E., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., and Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanism of formation involving reactive oxygen species. J. Neurochem. 71 (1998) 2112-2122
24. Wharton D.C., and Tzagoloff A. Cytochrome oxidase from beef heart mitochondria. Methods Enzymol. 10 (1967) 245-250